Vertex Pharmaceuticals Shares Drop After Phase 2 Results

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) fell 12% today following the announcement of the Phase 2 study results for suzetrigine, an investigational pain signal inhibitor. Though the drug met its primary endpoint, it did not show a significant difference from the placebo, leading to concerns about its efficacy.

The study focused on patients with painful lumbosacral radiculopathy (LSR) and reported a statistically significant reduction in pain on the Numeric Pain Rating Scale (NPRS) at Week 12 in the suzetrigine group. However, the placebo group demonstrated a similar reduction, raising questions about the drug's effectiveness. The primary endpoint measured the change from baseline in the weekly average of daily leg pain intensity, with the suzetrigine group showing a mean change of -2.02 points compared to the placebo's -1.98 points.

Despite achieving the primary endpoint, skepticism arose due to the lack of differentiation from placebo results. Stifel analyst Paul Matteis remarked, "In our view, the suzetrigine LSR result looks like a pretty clear negative…both improved by ~2 points on the NPRS at week 12, which is pretty unequivocal."

Vertex acknowledged the high placebo response but remains committed to advancing suzetrigine to Phase 3. The company plans to innovate study designs to better control for placebo effects and noted that the drug has a generally well-tolerated safety profile with no serious adverse events.

Further, Vertex is engaging in regulatory discussions for suzetrigine's progression in treating painful LSR and is continuing its pivotal program for painful diabetic peripheral neuropathy (DPN). Suzetrigine is also undergoing FDA review for treating moderate-to-severe acute pain, with a PDUFA target date of January 30, 2025.

As the market reacts to these results, investors will closely monitor Vertex's next steps and potential adjustments to clinical trial designs to address current challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.